Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study.

Background: Anxiety disorders and treatment-resistant major depressive disorder (TRD) are often comorbid. Studies suggest ketamine has anxiolytic and antidepressant properties.

Aims: To investigate if subcutaneous racemic ketamine, delivered twice weekly for 4 weeks, reduces anxiety in people with TRD.

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Background: Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD).

Assessing the prevalence of personality pathology in Australian psychiatric emergency care centres: A feasibility study.

Objectives: To assess feasibility and acceptability of self-report measures in estimating prevalence of measurable personality disorder (PD) pathology in a Psychiatric Emergency Care Centre (PECC) unit.

Method: Patients meeting eligibility criteria admitted to an inner-city PECC unit were invited to complete the (1) Standardised Assessment of Personality - Abbreviated Scale (SAPAS), (2) Personality Inventory of DSM-5 Brief Form (PID-5-BF), and (3) Level of Personality Functioning Scale - Brief Form 2.0 (LPFS-BF-2.

Integrating digital behavioural therapy for insomnia into primary care: A feasibility mixed-methods study.

Digital cognitive behavioural therapy for insomnia has been developed to increase capacity and scalability for patients with insomnia, but implementation in primary care remains limited. The aim of the trial was to evaluate the implementation of digital insomnia therapy into primary care practice for patients with insomnia. We conducted a single-arm feasibility trial of digital behavioural therapy for insomnia (SleepFix) providing sleep restriction therapy with insomnia patients in primary care.